Physician profile
Mark Lee Douglas
NPI 1306974464
$1,855.25
in general payments reported to CMS, 2019-2025
14 companies · $74.86 in 2025
The $74.86 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $272 · 2021: $423 · 2022: $173 · 2023: $14.94 · 2024: $30.81 · 2025: $74.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $120.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $365.37 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $230.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $224.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $203.07 | 2019-2021 | |
| Novo Nordisk INC | $170.39 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $169.85 | 2019-2020 | |
| Glaxosmithkline, LLC. | $136.47 | 2020-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $124.34 | 2019-2021 | |
| Allergan, INC. | $73.12 | 2019-2020 | |
| Medtronic, INC. | $44.11 | 2024-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.32 | 2019-2021 | |
| Abbvie INC. | $37.93 | 2021 | |
| Abbott Laboratories | $24.06 | 2022 | |
| Pfizer INC. | $12.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.